Crinetics Pharmaceuticals, Inc. (CRNX)

NMS – Real Time Price. Currency in USD

36.91

+0.36 (0.98%)

At close: May 12, 2026, 4:00 PM EDT

36.99

+0.08 (0.22%)

After-hours: May 12, 2026, 5:25 PM EDT

08.05.2026

Crinetics Pharmaceuticals, Inc. (CRNX) Q1 2026 Earnings Call Transcript

07.05.2026

Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q1 Loss, Beats Revenue Estimates

Crinetics Pharmaceuticals, Inc. (CRNX) came out with a quarterly loss of $1.23 per share versus the Zacks Consensus Estimate of a loss of $1.22. This compares to a loss of $1.04 per share a year ago.

07.05.2026

Crinetics Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update

PALSONIFY™ (Paltusotine) Net Product Revenue of $10.3 Million for First-Quarter 2026, with 232 Enrollment Forms in the First Quarter Management Hosting Conference Call at 4:30 p.m. ET Today SAN DIEGO, May 07, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a global pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for endocrine diseases and endocrine-related tumors, today reported financial results for the first quarter ended March 31, 2026.

30.04.2026

Analysts Estimate Crinetics Pharmaceuticals, Inc. (CRNX) to Report a Decline in Earnings: What to Look Out for

CRINETICS PHARM (CRNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

27.04.2026

Crinetics Pharmaceuticals Announces the European Commission Approval of PALSONIFY® (Paltusotine) for the Treatment of Acromegaly in Adults

PALSONIFY is the first once-daily, oral therapy approved to treat acromegaly in the European Union Approval based on strength of data from two pivotal Phase 3 studies studying PALSONIFY in both medical naïve and previously treated patients with acromegaly Crinetics' first regulatory approval outside of the U.S., with first launch planned for Germany and Austria SAN DIEGO, April 27, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that the European Commission (EC) has approved PALSONIFY® (paltusotine), the first once-daily, oral, selectively-targeted somatostatin receptor type 2 nonpeptide agonist, for the treatment of adult patients with acromegaly. “The European Commission's decision to approve Palsonify reflects the strength of the clinical data and marks a pivotal step toward bringing this important therapy to even more people living with acromegaly,” said Scott Struthers, Ph.D.

08.04.2026

Crinetics Pharmaceuticals to Report First Quarter 2026 Financial Results on May 7, 2026

SAN DIEGO, April 08, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that it will report first quarter 2026 financial results on Thursday, May 7, 2026 after the market closes. Company management will host a conference call at 4:30 p.m. ET to discuss financial results and provide a business update.

27.03.2026

Crinetics Director Sells 5,000 Shares With Stock Down 4%, but Here's What Matters More

A director of Crinetics Pharmaceuticals reported that he sold 5,000 shares of the company for a transaction value of approximately $180,761 on March 12, 2026. The sale represented 23.47% of Coelho's direct common stock holdings, reducing direct ownership from 21,300 to 16,300 shares.

Videos

No Data

There is no data to display

Press releases

07.05.2026

Crinetics Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update

27.04.2026

Crinetics Pharmaceuticals Announces the European Commission Approval of PALSONIFY® (Paltusotine) for the Treatment of Acromegaly in Adults

26.03.2026

Crinetics Pharmaceuticals Announces Submission of Marketing Authorization Application in Brazil for Palsonify™ (Paltusotine) in Acromegaly

SAN DIEGO, March 26, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced the submission of a Marketing Authorization Application (MAA) to Brazil's National Health Surveillance Agency (ANVISA) for PALSONIFY™ (paltusotine), the first once-daily, oral, selectively-targeted somatostatin receptor type 2 nonpeptide agonist, for the proposed treatment of acromegaly in adults. “The submission of our MAA for Palsonify in Brazil represents another important global milestone for this important therapy,” said Scott Struthers, Ph.D.

26.02.2026

Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

PALSONIFY™ (Paltusotine) Net Product Revenue of $5.4 Million for Fourth-Quarter 2025, with >200 Enrollment Forms at the End of December

Crinetics Pharmaceuticals, Inc. (CRNX)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Crinetics Pharmaceuticals, Inc. (CRNX)

Crinetics Pharmaceuticals, Inc. (CRNX) Q1 2026 Earnings Call Transcript

Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q1 Loss, Beats Revenue Estimates

Crinetics Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update

Analysts Estimate Crinetics Pharmaceuticals, Inc. (CRNX) to Report a Decline in Earnings: What to Look Out for

Crinetics Pharmaceuticals Announces the European Commission Approval of PALSONIFY® (Paltusotine) for the Treatment of Acromegaly in Adults

Crinetics Pharmaceuticals to Report First Quarter 2026 Financial Results on May 7, 2026

Crinetics Director Sells 5,000 Shares With Stock Down 4%, but Here's What Matters More

Videos

No Data

Press releases

Crinetics Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update

Crinetics Pharmaceuticals Announces the European Commission Approval of PALSONIFY® (Paltusotine) for the Treatment of Acromegaly in Adults

Crinetics Pharmaceuticals Announces Submission of Marketing Authorization Application in Brazil for Palsonify™ (Paltusotine) in Acromegaly

Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Crinetics Pharmaceuticals, Inc. (CRNX) Q1 2026 Earnings Call Transcript

Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q1 Loss, Beats Revenue Estimates

Crinetics Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update

Analysts Estimate Crinetics Pharmaceuticals, Inc. (CRNX) to Report a Decline in Earnings: What to Look Out for

Crinetics Pharmaceuticals Announces the European Commission Approval of PALSONIFY® (Paltusotine) for the Treatment of Acromegaly in Adults

Crinetics Pharmaceuticals to Report First Quarter 2026 Financial Results on May 7, 2026

Crinetics Director Sells 5,000 Shares With Stock Down 4%, but Here's What Matters More

Videos

No Data

Press releases

Crinetics Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update

Crinetics Pharmaceuticals Announces the European Commission Approval of PALSONIFY® (Paltusotine) for the Treatment of Acromegaly in Adults

Crinetics Pharmaceuticals Announces Submission of Marketing Authorization Application in Brazil for Palsonify™ (Paltusotine) in Acromegaly

Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Search stocks

Crinetics Pharmaceuticals, Inc. (CRNX)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Crinetics Pharmaceuticals, Inc. (CRNX)

Crinetics Pharmaceuticals, Inc. (CRNX) Q1 2026 Earnings Call Transcript

Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q1 Loss, Beats Revenue Estimates

Crinetics Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update

Analysts Estimate Crinetics Pharmaceuticals, Inc. (CRNX) to Report a Decline in Earnings: What to Look Out for

Crinetics Pharmaceuticals Announces the European Commission Approval of PALSONIFY® (Paltusotine) for the Treatment of Acromegaly in Adults

Crinetics Pharmaceuticals to Report First Quarter 2026 Financial Results on May 7, 2026

Crinetics Director Sells 5,000 Shares With Stock Down 4%, but Here's What Matters More

Videos

No Data

Press releases

Crinetics Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update

Crinetics Pharmaceuticals Announces the European Commission Approval of PALSONIFY® (Paltusotine) for the Treatment of Acromegaly in Adults

Crinetics Pharmaceuticals Announces Submission of Marketing Authorization Application in Brazil for Palsonify™ (Paltusotine) in Acromegaly

Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Crinetics Pharmaceuticals, Inc. (CRNX) Q1 2026 Earnings Call Transcript

Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q1 Loss, Beats Revenue Estimates

Crinetics Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update

Analysts Estimate Crinetics Pharmaceuticals, Inc. (CRNX) to Report a Decline in Earnings: What to Look Out for

Crinetics Pharmaceuticals Announces the European Commission Approval of PALSONIFY® (Paltusotine) for the Treatment of Acromegaly in Adults

Crinetics Pharmaceuticals to Report First Quarter 2026 Financial Results on May 7, 2026

Crinetics Director Sells 5,000 Shares With Stock Down 4%, but Here's What Matters More

Videos

No Data

Press releases

Crinetics Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update

Crinetics Pharmaceuticals Announces the European Commission Approval of PALSONIFY® (Paltusotine) for the Treatment of Acromegaly in Adults

Crinetics Pharmaceuticals Announces Submission of Marketing Authorization Application in Brazil for Palsonify™ (Paltusotine) in Acromegaly

Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update